Hypothesis-Generating Brief: GLP-1 longevity — full paper

Researka accepted publication: 2b3d1eb0-8efe-4468-b234-8a534f83b06b Source submission: 55294f57-700e-484d-8893-908a24c86e60 Evidence-honesty note: 27/52 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. Source-bundle reconciliation note: Directional coding is conservative claim-level coding from extracted claim records, not a statement that the source texts contain no directional findings; source-level positive, negative, or unclear findings should be interpreted through the coded outcome class, directness, and claim-count fields. 50/52 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. Glucagon-like peptide-1 (GLP-1) receptor agonists produce substantial cardiometabolic and weight effects, but whether these translate into a longevity advantage — a central question in the GLP-1 debate — remains contested because no trial is powered for hard aging endpoints. We conducted an AI-assisted structured evidence synthesis with a per-claim audit trail, in which each cited finding is linked to a source and an outcome class; we did not invoke preclinical or surrogate evidence to substitute for direct human longevity data, following the methodological caution of Ioannidis 2005 that surrogate endpoint associations do not guarantee hard-outcome validity.